Monitoring relapsing remitting MS patients

Journal of Neuroimmunology

Volumn 98, Issue 1, 1999, Pages 16-21

  Bourdette, Dennis ^a   Antel, Jack ^b   McFarland, Henry ^c   Montgomery Jr , Erwin ^d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Immunomodulation; Magnetic resonance imaging; Multiple sclerosis; Treatment

Indexed keywords

BETA INTERFERON; GLATIRAMER;

CONFERENCE PAPER; DEMYELINATION; DISEASE ACTIVITY; HUMAN; IMMUNOMODULATION; MONITORING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE;

BRAIN; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 0033047928     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00076-4     Document Type: Conference Paper

References (24)

1. Arnason B.G.W., Reder A.T. Interferons and multiple sclerosis. Clin. Neuropharmacol. 17:1994;495-547.
2. Ebers, G.C., 1997. Immunology. In: Paty, D.W., Ebers, G.C. (Eds.), Multiple Sclerosis. FA Davis, Philadelphia, pp. 403-426.
3. Filippi M., Horsfield M.A., Morrissey S.P., MacManus D.G., Rudge P., McDonald W.I., Miller D.H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 44:1994;635-641.
4. Franklin G.W., Heaton R.K., Nelson L.M., Filley C.M., Seibert C. Correlation of neuropsychological and MRI findings in chronic/progressive multiple sclerosis. Neurology. 38:1988;1826-1829.
5. Goodkin D.E., Hertsgaard D., Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with Box-and-Block and Nine-Hole Peg Tests. Arch. Phys. Med. Rehab. 69:1988;850-854.
6. Harris J.O., Frank J.A., Patronas N., McFarlin D.E., McFarland H.F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol. 29:1991;548-555.
7. Mancardi G.L., Sardanelli F., Parodi R.C., Melani E., Capello E., Inglese M., Ferrari A., Sormani M.P., Ottonello C., Levrero F., Uccelli A., Bruzzi P. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology. 50:1998;1127-1133.
8. McFarland, H.F., Richert, N., Frank, J., 1999. Blood brain barrier disruption in the evolution of the lesion in multiple sclerosis: role in monitoring disease activity. J. Neuroimmunol. (submitted).
9. Michels R., Wessel K., Klohn S., Kompf D. Long-latency reflexes, somatosensory evoked potentials and transcranial mangetic stimulation: relation of the three methods in multiple sclerosis. Electroencephalogr. Clin. Neurophysiol. 89:1993;235-241.
10. Miller, D.H., 1997. Assigning prognosis. In: Miller, D.H., Kesselring, J., McDonald, W.I., Paty, D.W., Thompson, A.J. (Eds.), Magnetic Resonance in Multiple Sclerosis. Cambridge University Press, Cambridge, pp. 108-125.
11. Paty D.W. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can. J. Neurol. Sci. 15:1988;266-272.
12. The UBC MS/MRI Study group and the IFNB Multiple Sclerosis Study Group, Paty D.W., Li D.K.B. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
13. Paty, D.W., Noseworthy, J.H., Ebers, G.C., 1997. Diagnosis of multiple sclerosis. In: Paty, D.W., Ebers, G.C. (Eds.), Multiple Sclerosis. F.A. Davis, Philadelphia, pp. 48-134.
14. Peyser J.M., Edwards K.R., Poser C.M., Filskov S.B. Cognitive function in patients with multiple sclerosis. Arch. Neurol. 37:1980;577-579.
15. Pliskin N.H., Hamer D.P., Goldstein D.S., Towle V.L., Reder A.T., Noronha A., Arnason B.G. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 47:1996;1463-1468.
16. Rao, S.M., Leo, G.J., Haughton, V.M., St. Aubin-Faubert, P., Bernardin, L., 1989. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. 39, 161-166.
17. Schwid S.R., Goodman A.D., Mattson D.H., Mihai C., Donohoe K.M., Petrie M.D., Scheid E.A., Dudman J.T., McDermott M.P. The measurement of ambulatory impairment in multiple sclerosis. Neurology. 49:1997;1419-1424.
18. Stone L.A., Frank J.A., Albert P.S., Bash C.N., Calabresi P.A., Maloni H., McFarland H.F. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology. 49:1997;862-869.
19. Teitelbaum D., Aharoni R., Arnon R., Sela M. Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer 1. Proc. Natl. Acad. Sci. USA. 85:1988;9724-9728.
20. Teitelbaum D., Milo R., Arnon R., Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc. Natl. Acad. Sci. USA. 89:1992;137-141.
21. The Multiple Sclerosis Collaborative Research Group (MSCRG), Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Fischer J.S., Goodkin D.E., Granger C.V., Simon J.H., Alam J.J., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Weinstock-Guttman B., Whitham R.H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
22. The Copolymer 1 Multiple Sclerosis Study Group, Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P., Myers L.W., Panitch H.S., Rose J.W., Schiffer R.B., Vollmer T., Weiner L.P., Wolinsky J.S. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology. 45:1995;1268-1276.
23. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
24. Thompson A.J., Miller D., Youi B., MacManus D., Moore S., Kingsley D., Kendall B., Feinstein A., McDonald W.I. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology. 42:1992;60-63.